{
    "clinical_study": {
        "@rank": "154766", 
        "arm_group": {
            "arm_group_label": "ATX-MS-1467", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, single arm, Phase 2a trial to evaluate the clinical and\n      biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to\n      assess the maintenance of any such effects."
        }, 
        "brief_title": "ATX-MS-1467 in Multiple Sclerosis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female out-patients aged 18 to 65 years of age inclusive at the time of\n             informed consent\n\n          -  Willing and able to provide written informed consent and to comply with the\n             requirements of the protocol assessments/procedures\n\n          -  Relapsing MS (relapsing-remitting multiple sclerosis [RRMS], secondary progressive\n             multiple sclerosis [SPMS] or clinically isolated syndrome[CIS], as defined by the\n             revised McDonald criteria [2010]) (11)\n\n          -  Clinical evidence of recent MS activity and radiological activity on gadolinium\n             (Gd)-enhanced magnetic resonance imaging (MRI) defined as defined in the protocol\n\n          -  Expanded disability status scale (EDSS) score 0-5.5\n\n          -  Human leukocyte antigen-beta chain (HLA-DRB)1*15 positive\n\n          -  Neurological stability in the 30 days prior to Visit 5 (Study Day 1)\n\n          -  Prior vaccination against tuberculosis (TB) and a positive tuberculin (purified\n             protein derivative [PPD]) skin test at Screening\n\n          -  If female, unless post-menopausal (for at least 2 years) or surgically sterilized,\n             must be willing to use two highly effective methods of contraception throughout the\n             entire duration of the trial and for 90 days following the last dose of ATX-MS-1467\n\n          -  If male, must be willing to use two highly effective methods of contraception\n             throughout the entire duration of the trial and for 90 days following the last dose\n             of ATX-MS-1467\n\n        Exclusion Criteria:\n\n          -  Primary progressive MS\n\n          -  Inability to comply with MRI scanning, including contra-indications to MRI such as\n             known allergy to gadolinium contrast dyes, claustrophobia, presence of a pacemaker,\n             cochlear implants, ferromagnetic devices or clips, intracranial vascular clips,\n             insulin pumps, nerve stimulators\n\n          -  Previous treatment with beta-interferon, plasma exchange, intravenous gamma globulin\n             within the 8 weeks prior to study Day 1 (Visit 5), steroids (administered via the\n             oral and/or parenteral routes) or adrenocorticotropic hormone within the 30 days\n             prior to the Visit 2 MRI scan, glatiramer acetate, cytotoxic agents\n\n          -  Prior exposure to dimethyl fumurate (BG-12) or dirucotide, any disease-related T cell\n             vaccine or peptide-tolerizing agent for the treatment of MS, including ATX-MS-1467\n\n          -  Use of any investigational drug or experimental procedure for MS (including cytokine\n             or anticytokine therapy) within the 30 days prior to screening (Visit 1)\n\n          -  Inadequate liver function as defined in the protocol.\n\n          -  Lymphocyte count less than (<)500 per micro liter (/mcL) or neutrophil count < 1500\n             mcL at screening or at any of the pre-treatment visits (Visits 2-4)\n\n          -  Major medical illness as defined in the protocol\n\n          -  Known history of active or chronic infectious disease or any disease which\n             compromises immune function\n\n          -  Any renal condition that would preclude the administration of gadolinium\n\n          -  History of malignancy, including both solid tumor and hematological malignancies, but\n             excluding basal cell and in situ squamous cell carcinomas of the skin that have been\n             excised and resolved, in situ cervical cancer or prostatic cancer with normal\n             prostatic specific antigen\n\n          -  Clinical evidence of severe uncontrolled depression, active suicidal ideation or\n             suicide attempt\n\n          -  Any other significant medical or psychiatric conditions that, in the opinion of the\n             Investigator, would preclude participation in the trial or impair the ability to give\n             informed consent\n\n          -  Major surgery in the 4 weeks prior to screening (Visit 1)\n\n          -  Known hypersensitivity to the trial medication or diluents\n\n          -  Participation in another clinical trial within the 30 days prior to screening (Visit\n             1)\n\n          -  Pregnancy, lactation or a positive pregnancy test during screening (urine dipstick)\n             or at Visit 4 (serum beta-human chorionic gonadotrophin [beta-hCG]), or intention to\n             become pregnant or to breast-feed during the course of the trial\n\n          -  Legal incapacity or limited legal capacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973491", 
            "org_study_id": "200166-001", 
            "secondary_id": "2013-002916-28"
        }, 
        "intervention": {
            "arm_group_label": "ATX-MS-1467", 
            "description": "ATX-MS-1467 will be administered as per dosage regimen specified in the protocol for 16 weeks.", 
            "intervention_name": "ATX-MS-1467", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ATX-MS-1467 (MSC2358825A)", 
            "Relapsing Multiple Sclerosis", 
            "Magnetic resonance imaging (MRI)"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49 6151 72 5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Russia: Ministry of Health of the Russian Federation", 
                "Latvia: State Agency of Medicines"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in the average number of time constant 1 (T1) contrast-enhanced lesions (CEL) at three on-treatment scans (Weeks 12, 16 and 20) compared to the average number of T1 CEL at three Baseline scans (Weeks -8, -4 and 0)", 
            "safety_issue": "No", 
            "time_frame": "Weeks -8, -4, 0, 12, 16 and 20"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of T1 CEL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Change from Baseline (average of 3 Baseline scans, Weeks -8, -4 and 0) in total number of T1 CEL at Weeks 12, 16, 20, 24, 28 and 36", 
                "safety_issue": "No", 
                "time_frame": "Weeks -8, -4, 0, 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Change from Baseline (average of 3 Baseline scans, Weeks -8, -4 and 0) in total volume of T1 CEL at Weeks 12, 16, 20, 24, 28 and 36", 
                "safety_issue": "No", 
                "time_frame": "Weeks -8, -4, 0, 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Number of new or newly enlarging time constant 2 (T2) lesions", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Change from Baseline (Week 0) in total number of T1  CEL at Weeks 12, 16, 20, 24, 28 and 36", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Change from Baseline (Week 0) in total volume of T1 CEL at Weeks 12, 16, 20, 24, 28 and 36", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 12, 16, 20, 24, 28 and 36"
            }, 
            {
                "measure": "Mean Annualized Relapse Rate", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Time to first relapse", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 36"
            }, 
            {
                "measure": "Change from Baseline (Week 0) in total expanded disability status scale (EDSS) score at Week 20", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 20"
            }, 
            {
                "measure": "Change from Baseline (Week 0) in total multiple sclerosis functional composite (MSFC) score at Week 20", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 20"
            }, 
            {
                "measure": "Change from Baseline (Week 0) in myelin basic protein (MBP)-induced peripheral blood mononuclear cells (PBMC) proliferation at Week 20", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and Week 20"
            }, 
            {
                "measure": "Change from Week 20 in MBP-PBMC proliferation at Week 36", 
                "safety_issue": "No", 
                "time_frame": "Week 20 and Week 36"
            }, 
            {
                "measure": "Number of subjects with treatment-emergent adverse events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Week 36"
            }, 
            {
                "measure": "Number of subjects experiencing injection site reactions (ISRs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Week 24"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}